doi:10.48130/git-0026-0010

[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74(3):229−263

doi: 10.3322/caac.21834

[2]

Luo W, Wang J, Chen H, Ye LY, Qiu J, et al. 2023. Epidemiology of pancreatic cancer: new version, new vision. Chinese Journal of Cancer Research 35(5):438−450

doi: 10.21147/j.issn.1000-9604.2023.05.03

[3]

Committee of Cancer Biotherapy CA-CA. 2024. Guidelines for the application of immunotherapy in malignant tumors (abridged version). Chinese Journal of Clinical Oncology 51:838−846

doi: 10.12354/j.issn.1000-8179.2024.20241096

[4]

Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, et al. 2025. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639:474−482

doi: 10.1038/s41586-024-08507-5

[5]

Liu ZK, Cheng WS, Wu WS, Liang TJ, Xing QZ, et al. 2023. Principles and clinical applications of boron neutron capture therapy. Medical Journal of Peking Union Medical College Hospital 14(4):698−705

doi: 10.12290/xhyxzz.2023-0120

[6]

Lin D, Shen Y, Liang T. 2023. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy 8(1):156

doi: 10.1038/s41392-023-01407-6

[7]

Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, et al. 2017. Trial watch: adoptively transferred cells for anticancer immunotherapy. Oncoimmunology 6(11):e1363139

doi: 10.1080/2162402x.2017.1363139

[8]

Hu C, Zhang Q, Liang T. 2024. Cellular therapy in pancreatic cancer. Tumor 44(12):1191−1208

doi: 10.3781/j.issn.1000-7431.2024.2409-0538

[9]

Chen H, Wei F, Yin M, Zhao Q, Liu Z, et al. 2021. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors. Cancer Immunology, Immunotherapy 70(7):2059−2071

doi: 10.1007/s00262-020-02838-8

[10]

Qi C, Zhang P, Liu C, Zhang J, Zhou J, et al. 2024. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. Journal of Clinical Oncology 42(21):2565−2577

doi: 10.1200/JCO.23.02314

[11]

Synnott D, O'Reilly D, De Freitas D, Naidoo J. 2025. Cytokine release syndrome in solid tumors. Cancer 131(17):e70069

doi: 10.1002/cncr.70069

[12]

Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM. 2022. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists. Journal of the American Academy of Dermatology 87(3):597−604

doi: 10.1016/j.jaad.2021.07.017

[13]

Storgard R, Dusza S, Shouval R, Scordo M, Markova A. 2024. Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system. Transplantation and Cellular Therapy 30(10):1035. e1–1035. e7

doi: 10.1016/j.jtct.2024.06.024

[14]

Chinese Society Dermatology of the Chinese Medical Association, Chinese Dermatologist Association of the Chinese Medical Doctor Association, Dermatology Division of the Chinese Geriatrics Society. 2024. Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition). National Medical Journal of China 104:1790−1803

doi: 10.3760/cma.J.Cn112137-20240112-00091

[15]

Chinese Stomatological Association. 2024. Expert consensus on prevention and treatment of radiotherapy/chemotherapy-induced oral mucositis. www.cndent.com/wp-content/uploads/2024/11/74-

[16]

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, et al. 2019. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation 25(4):625−638

doi: 10.1016/j.bbmt.2018.12.758

[17]

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, et al. 2010. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 182(18):E839−E842

doi: 10.1503/cmaj.090449

[18]

Joanna Briggs Institute. 2017. Critical appraisal tools for use in JBI systematic reviews: checklist for text and opinion. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Text_and_Opinion2017_0.pdf

[19]

Foster MJ, Shurtz S. 2013. Making the critical appraisal for summaries of evidence (CASE) for evidence-based medicine (EBM): critical appraisal of summaries of evidence. Journal of the Medical Library Association: JMLA 101(3):192−198

doi: 10.3163/1536-5050.101.3.008

[20]

Joanna Briggs Institute. 2014. New JBI levels of evidence. https://jbi.global/sites/default/files/2019-05/JBI-Levels-of-evidence_2014_0.pdf

[21]

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, et al. 2022. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology 33(12):1217−1238

doi: 10.1016/j.annonc.2022.10.001

[22]

Cury-Martins J, Eris APM, Abdalla CMZ, Silva GdB, Moura VPT, et al. 2020. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. Anais Brasileiros de Dermatologia 95(2):221−237

doi: 10.1016/j.abd.2020.01.001

[23]

Zheng JL, Liu T, Zheng B, Zheng XM, Li CH, et al. 2023. Summary of evidence on prevention and nursing of immune checkpoint inhibitor associated skin toxicity in lung cancer patients. Chinese Journal of Modern Nursing 29(35):4821−4828

doi: 10.3760/cma.j.cn115682-20230510-01837

[24]

National Comprehensive Cancer Network. 2025. NCCN Guidelines Version 1. 2025 Management of Immunotherapy-Related Toxicities. https://cdn.prod.website-files.com/659de0c2422a9587bd569340/679a6291efce30e91e7bd2d1_immunotherapy.pdf

[25]

Zhu G, Shi Q, Cai T, Gu D, Zhou H, et al. 2024. CACA guidelines for holistic integrative management of anticancer treatment-induced cutaneous adverse events. Holistic Integrative Oncology 3(1):33

doi: 10.1007/s44178-024-00095-8

[26]

Murillo-Casas AD, Zwiener R, Giavina-Bianchi P, Pardo-Manrique V, Villarreal-González R, et al. 2025. Latin American guidelines for the diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. World Allergy Organization Journal 18(4):101046

doi: 10.1016/j.waojou.2025.101046

[27]

Yang Z, Luo Y, Lu R, Liu X, Liu H, et al. 2024. Evidence based summary of the management for immune checkpoint inhibitor-related cutaneous toxicity. Journal of Nursing Science 39(20):46−50

doi: 10.3870/j.issn.1001-4152.2024.20.046

[28]

Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, et al. 2020. Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer 28(12):6119−6128

doi: 10.1007/s00520-020-05706-4

[29]

Chinese Dermatologist Association, Therapy Group of Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Specialty Committee on Rare Skin Diseases of China Alliance for Rare Diseases. 2025. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement (2025 edition). Chinese Journal of Dermatology 58(5):405−415

doi: 10.35541/cjd.20240622

[30]

Hu L, Peng H, Mi Y, Cao M, Hu M, et al. 2022. Evidence summary for prevention and management of the skin adverse reactions in patients with targeted tumor therapy. Chinese Journal of Nursing 57(9):1061−1069

doi: 10.3761/j.issn.0254-1769.2022.09.006

[31]

China Dermatologist Association. 2024. Guidelines for the management of chronic pruritus. Chinese Journal of Dermatology 57(5):387−399

doi: 10.35541/cjd.20230746

[32]

China Dermatologist Association. 2023. Guidance on application of moisturizers and emollients: an expert consensus. Chinese Journal of Dermatology 56(8):711−717

doi: 10.35541/cjd.20230133

[33]

Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, et al. 2021. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. Journal of the European Academy of Dermatology & Venereology 36(3):332−350

doi: 10.1111/jdv.17855

[34]

Chinese Society of Clinical Oncology. 2024. CSCO guidelines for CAR-T Cell therapy of malignant hematological diseases 2024. Beijing: People's Medical Publishing House. www.csco.org.cn

[35]

Chinese Society of Clinical Oncology Expert Committee on Safety Management of Anti-tumor Drugs, Chinese Society of Clinical Oncology Expert Committee on Supportive and Rehabilitation Care in Cancer. 2021. Expert consensus on diagnosis, prevention and treatment of acute oral mucositis induced by antitumor therapy. Chinese Clinical Oncology 26:449−459

[36]

United Kingdom Oral Mucositis in Cancer Group Guidelines. 2015. Mouth care guidance and support in cancer and palliative care. www.stlukes-hospice.org.uk/wp-content/uploads/2017/06/UK_OM_Guidelines_v3.pdf (accessed on August 2025)

[37]

Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, et al. 2021. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 9(6):e002435

doi: 10.1136/jitc-2021-002435

[38]

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, et al. 2021. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology 39:4073−4126

doi: 10.1200/jco.21.01440

[39]

Subspecialty Committee on Autoimmune Diseases, China Dermatologist Association. 2018. Expert consensus on the treatment of immune-related dermatosis with glucocorticoid. Chinese Journal of Allergy and Clinical Immunology 12:1−7

doi: 10.3969/j.issn.1673-8705.2018.01.001

[40]

Ellard R, Kenyon M, Hutt D, Aerts E, de Ruijter M, et al. 2022. The EBMT immune effector cell nursing guidelines on CAR-T therapy: a framework for patient care and managing common toxicities. Clinical Hematology International 4(3):75−88

doi: 10.1007/s44228-022-00004-8

[41]

Yin Y, Zhao K, Wang C, Tang L, He H, et al. 2025. Chinese expert consensus on clinical management of the psychosomatic symptoms in patients with cancer. Chinese General Practice 28(15):1809−1822

doi: 10.12114/j.issn.1007-9572.2024.0575

[42]

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, et al. 2022. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology 33(3):259−275

doi: 10.1016/j.annonc.2021.12.003

[43]

Shanghai Pharmaceutical Industry Association. 2023. Research guidelines for long-term follow-up of chimeric antigen receptor T cell (CAR-T) therapy products (T/SHPPA 023-2023). https://qxb-img-osscache.qixin.com/standards/8194edd081ee4a6195a3a93fa611c7ca.pdf

[44]

Hu Y, Zheng W, Qiao J, Cui Q, Zhu Y, et al. 2020. Bullous and exanthematous lesions associated with chimeric antigen receptor T-cell therapy in a patient with diffuse large B-cell lymphoma. JAMA Dermatology 156(9):1026−1028

doi: 10.1001/jamadermatol.2020.0636

[45]

Vaez-Gharamaleki Y, Akbarzadeh MA, Jadidi-Niaragh F, Mahmoodpoor A, Sanaie S, et al. 2025. Dermatologic toxicities related to cancer immunotherapy. Toxicology Reports 14:102021

doi: 10.1016/j.toxrep.2025.102021

[46]

Freites-Martínez A, Santana N, Arias-Santiago S, Viera A. 2021. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliográficas (English Edition) 112(1):90−92

doi: 10.1016/j.ad.2019.05.009

[47]

Yang XJ, Zhou ML, Zhang HQ, He JJ. 2022. Nursing care for 4 patients with severe cutaneous toxicity induced by PD-1 antibody therapy. Modern Nurse 29(14):139−141

doi: 10.19792/j.cnki.1006-6411.2022.14.042

[48]

Zulkowski K. 2017. Understanding moisture-associated skin damage, medical adhesive-related skin injuries, and skin tears. Advances in Skin & Wound Care 30(8):372−381

doi: 10.1097/01.ASW.0000521048.64537.6e.

[49]

Nguyen N, Dulai AS, Adnan S, Khan Z-e-h, Sivamani RK. 2025. Narrative review of the use of hydrocolloids in dermatology: applications and benefits. Journal of Clinical Medicine 14(4):1345

doi: 10.3390/jcm14041345

[50]

National Health Commission. 2023. Hospital isolation technical standard. Beijing: China Standard Press. www.nhc.gov.cn/fzs/c100048/202309/da0e35a3d5574df69faf2d5dae7e1351/files/1733125848948_13763.pdf

[51]

Dermatologic Laser and Cosmetic Group of Chinese Society of Dermatology, Research Center of Dermatologic Laser Technology of Chinese Medical Association, Laser Subspecialty Committee of Chinese Society of Aesthetic and Plastic Surgeons. 2019. Chinese dermatologist consensus about application of recombinant bovine basic fibroblast growth factor(rb-bFGF)for laser and IPLS treatment and skin barrier repairment. Journal of Practical Dermatology 12(6):321−323

doi: 10.11786/sypfbxzz.1674-1293.20190601

[52]

Yosipovitch G, Gooderham MJ, Ständer S, Fonacier L, Szepietowski JC, et al. 2023. Interpreting the relationship among itch, sleep, and work productivity in patients with Moderate-to-Severe atopic dermatitis: a post hoc analysis of JADE MONO-2. American Journal of Clinical Dermatology 25(1):127−138

doi: 10.1007/s40257-023-00810-7

[53]

Nadelmann ER, Yeh JE, Chen ST. 2022. Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors. JAMA Oncology 8(1):130−138

doi: 10.1001/jamaoncol.2021.4318

[54]

Yu YT, Deng JL, Jin XR, Zhang ZZ, Zhang XH, et al. 2020. Effects of 9 oral care solutions on the prevention of oral mucositis: a network meta-analysis of randomized controlled trials. Medicine (Baltimore) 99(16):e19661

doi: 10.1097/md.0000000000019661

[55]

Cheng Y, Qin SK, Chen YP, Dong LH, Sun XD, et al. 2018. Local analgesic effect of a bioadhesive barrier-forming oral liquid in cancer patients with oral mucositis caused by chemotherapy and/or radiotherapy: a randomized multicenter, single-use, positive-controlled, open-label study. OncoTargets and Therapy 11:8555−8564

doi: 10.2147/ott.S185915

[56]

Ding X, Wu M, Zhang Y, Liu Y, Han Y, et al. 2023. The prevalence of depression and suicidal ideation among cancer patients in mainland China and its provinces, 1994–2021: a systematic review and meta-analysis of 201 cross-sectional studies. Journal of Affective Disorders 323:482−489

doi: 10.1016/j.jad.2022.12.011

[57]

Xie C, Duan H, Liu H, Wang Y, Sun Z, et al. 2024. Promoting patient-centered care in CAR-T therapy for hematologic malignancy: a qualitative meta-synthesis. Supportive Care in Cancer 32(9):591

doi: 10.1007/s00520-024-08799-3

[58]

Grégoire C, Melenhorst JJ. 2024. Navigating CAR-T cell therapy long-term complications. Nature Cancer 5(12):1768−1770

doi: 10.1038/s43018-024-00867-1

[59]

Camacho-Arteaga L, Iacoboni G, Kwon M, Bailén R, Hernani R, et al. 2025. Late adverse events after chimeric antigen receptor T-cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma. JAMA Network Open 8(2):e2461683

doi: 10.1001/jamanetworkopen.2024.61683

[60]

Chavez JC, Jain MD, Kharfan-Dabaja MA. 2020. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: a comprehensive review of emerging grading models. Hematology/Oncology and Stem Cell Therapy 13(1):1−6

doi: 10.1016/j.hemonc.2019.05.005

[61]

Ren S, Qin B, Daniels MJ, Zeng L, Tian Y, et al. 2025. Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer. World Journal of Radiology 17(8):109373

doi: 10.4329/wjr.v17.i8.109373

[62]

Drougkas K, Karampinos K, Karavolias I, Gomatou G, Koumprentziotis IA, et al. 2024. CAR-T cell therapy in pancreatic and biliary tract cancers: an updated review of clinical trials. Journal of Gastrointestinal Cancer 55(3):990−1003

doi: 10.1007/s12029-024-01054-2

[63]

Dong J, Wu J, Jin Y, Zheng Z, Su T, et al. 2025. In-depth analysis of the safety of CAR-T cell therapy for solid tumors. Frontiers in Immunology 16:1548979

doi: 10.3389/fimmu.2025.1548979

[64]

Miranda JA, Huvet C, Donzel M, Lazareth A, Perrot J, et al. 2023. Sudden-onset painful eruption of the hands: a cutaneous chimeric antigen receptor T-cell therapy reaction. JAAD Case Reports 40:92−95

doi: 10.1016/j.jdcr.2023.07.042

[65]

Quan IL, Trupiano N, Park J, Nguyen C, Zheng LD. 2025. CAR T-cell therapy: considerations for the inpatient dermatologist. Current Dermatology Reports 14(1):20

doi: 10.1007/s13671-025-00472-0

[66]

Liu JQ, Zhang, YJ. 2024. Strategies for prevention, control and management of CAR-T cell therapy related adverse reactions. Chin J of Oncol Prev and Treat 16(5):540−548

doi: 10.3969/j.issn.1674-5671.2024.05.05

[67]

Morris EC, Neelapu SS, Giavridis T, Sadelain M. 2022. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology 22(2):85−96

doi: 10.1038/s41577-021-00547-6

[68]

Gofshteyn JS, Shaw PA, Teachey DT, Grupp SA, Maude S, et al. 2018. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology 84(4):537−546

doi: 10.1002/ana.25315

[69]

Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, et al. 2018. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine 16(1):94

doi: 10.1186/s12967-018-1467-x

[70]

Liu Y, Guo Y, Wu Z, Feng K, Tong C, et al. 2020. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22(10):573−580

doi: 10.1016/j.jcyt.2020.04.088

[71]

Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, et al. 2017. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. Journal of Hematology & Oncology 10(1):4

doi: 10.1186/s13045-016-0378-7

[72]

Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV. 2021. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. European Journal of Cancer 157:214−224

doi: 10.1016/j.ejca.2021.08.031

[73]

Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, et al. 2023. Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel) 15(5):1629

doi: 10.3390/cancers15051629

[74]

Zhang L, Zhao L, Lin X, Zhao S, Pan WB, et al. 2024. Comparison of tumor non-specific and PD-L1 specific imaging by near-infrared fluorescence/cerenkov luminescence dual-modality in-situ imaging. Molecular Imaging 23:15353508241261473

doi: 10.1177/15353508241261473

[75]

Serra-López J, Miranda A, Soria A, López N, Castañón E, et al. 2025. Guía para enfermeras sobre el manejo de pacientes en tratamiento oncológico con inmunoterapia. Enfermería Clínica 35(6):502193

doi: 10.1016/j.enfcli.2025.502193

[76]

Sumi T, Kanamaru K, Tsuji S, Kagawa M, Ishigooka T, et al. 2026. Prophylactic interventions to prevent severe skin toxicities in patients with non-small cell lung cancer treated with nivolumab + ipilimumab with or without chemotherapy. JCO Oncology Practice 22(4):602−610

doi: 10.1200/op-25-00100

[77]

Siddiqui MA, Usmani A, Ansari MN, Almoselhy RIM. 2025. Immune-related adverse events in immunotherapy: challenges in diagnosis, monitoring, and management. Toxicology Reports 14:102036

doi: 10.1016/j.toxrep.2025.102036